Cancer Stem Cell Resistance to Targeted Therapy
Cancer Stem Cell Resistance to Targeted Therapy
Buch
- Herausgeber: Cristina Maccalli, Soldano Ferrone, Matilde Todaro
lieferbar innerhalb 2-3 Wochen
(soweit verfügbar beim Lieferanten)
(soweit verfügbar beim Lieferanten)
EUR 120,46**
EUR 109,51*
- Springer International Publishing AG, 08/2020
- Einband: Kartoniert / Broschiert, Paperback
- Sprache: Englisch
- ISBN-13: 9783030166267
- Bestellnummer: 10283395
- Umfang: 276 Seiten
- Nummer der Auflage: 20001
- Auflage: 1st ed. 2019
- Gewicht: 423 g
- Maße: 235 x 155 mm
- Stärke: 14 mm
- Erscheinungstermin: 14.8.2020
- Serie: Resistance to Targeted Anti-Cancer Therapeutics - Band 19
Achtung: Artikel ist nicht in deutscher Sprache!
Weitere Ausgaben von Cancer Stem Cell Resistance to Targeted Therapy
Klappentext
This book represents an up-dated summary of the state of the art of the characterization of cancer stem cell/ cancer initiating cell (CSC/CIC) properties. An overview of the definition and biological properties of CSCs / CICs as well as the role of these cells in determining the resistance to standard and immune-based therapies is provided. It also discusses limitations in the achievement of a definitive biological characterization of CSCs / CICs due to their high extent of plasticity and heterogeneity that is also mutually driven by the interaction of these cells with the tumor microenvironment. The limitations in targeting CSCs / CICs with immunotherapy are also explained together with explorative combination approaches that could increase the susceptibility of these cells to the recognition by immune cells.This book is conceived for a broad audience, including students, teachers, scientific experts. The critical revision of available results in terms of immunological profile of CSCs / CICs and the efficacy in targeting these cells by immunological approaches, results in a comprehensive and up to date recapitulation of the field and provides interesting suggestions on how to focus future investigations in order to assess the role of CSCs / CICs as prognostic and predictive biomarkers of responsiveness to therapies for cancer patients.